Market Closed -
Sao Paulo
04:06:00 2024-04-30 pm EDT
|
5-day change
|
1st Jan Change
|
20.19
BRL
|
+13.62%
|
|
+26.19%
|
+249.31%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
390.4
|
753.4
|
1,098
|
879.7
|
551.9
|
469.8
|
Enterprise Value (EV)
1 |
454.9
|
804.3
|
1,144
|
1,009
|
619.7
|
594.7
|
P/E ratio
|
-8.14
x
|
-10.8
x
|
-14
x
|
-11
x
|
-5.37
x
|
-5.93
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
249
x
|
84.2
x
|
18.7
x
|
8.21
x
|
5.26
x
|
3.98
x
|
EV / Revenue
|
290
x
|
89.9
x
|
19.5
x
|
9.42
x
|
5.9
x
|
5.03
x
|
EV / EBITDA
|
-13
x
|
-16.3
x
|
-24.7
x
|
-18
x
|
-8.1
x
|
-9.74
x
|
EV / FCF
|
-15.7
x
|
-21.5
x
|
-15.6
x
|
-15.1
x
|
-17.4
x
|
-12.2
x
|
FCF Yield
|
-6.36%
|
-4.65%
|
-6.42%
|
-6.64%
|
-5.74%
|
-8.23%
|
Price to Book
|
3.68
x
|
4.91
x
|
5.73
x
|
7.88
x
|
3.47
x
|
4.21
x
|
Nbr of stocks (in thousands)
|
47,783
|
60,760
|
67,716
|
67,776
|
81,288
|
81,288
|
Reference price
2 |
8.170
|
12.40
|
16.21
|
12.98
|
6.790
|
5.780
|
Announcement Date
|
3/28/19
|
3/27/20
|
3/26/21
|
3/25/22
|
3/23/23
|
3/27/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
1.566
|
8.944
|
58.67
|
107.1
|
105
|
118.2
|
EBITDA
1 |
-35.03
|
-49.38
|
-46.37
|
-56.05
|
-76.46
|
-61.04
|
EBIT
1 |
-36.67
|
-52.61
|
-55.3
|
-65.65
|
-86.24
|
-72.52
|
Operating Margin
|
-2,341.89%
|
-588.22%
|
-94.25%
|
-61.3%
|
-82.17%
|
-61.36%
|
Earnings before Tax (EBT)
1 |
-42.53
|
-55.77
|
-70.7
|
-79.79
|
-93.19
|
-80.8
|
Net income
1 |
-42.56
|
-55.81
|
-70.77
|
-80.26
|
-92.56
|
-81.14
|
Net margin
|
-2,717.88%
|
-624.02%
|
-120.62%
|
-74.95%
|
-88.19%
|
-68.65%
|
EPS
2 |
-1.004
|
-1.152
|
-1.158
|
-1.185
|
-1.263
|
-0.9751
|
Free Cash Flow
1 |
-28.94
|
-37.41
|
-73.41
|
-66.94
|
-35.55
|
-48.92
|
FCF margin
|
-1,847.73%
|
-418.26%
|
-125.13%
|
-62.51%
|
-33.88%
|
-41.39%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/28/19
|
3/27/20
|
3/26/21
|
3/25/22
|
3/23/23
|
3/27/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
64.5
|
50.9
|
46.2
|
129
|
67.7
|
125
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-1.84
x
|
-1.031
x
|
-0.9969
x
|
-2.302
x
|
-0.8858
x
|
-2.046
x
|
Free Cash Flow
1 |
-28.9
|
-37.4
|
-73.4
|
-66.9
|
-35.6
|
-48.9
|
ROE (net income / shareholders' equity)
|
-51.5%
|
-43%
|
-41%
|
-53%
|
-68.4%
|
-57.7%
|
ROA (Net income/ Total Assets)
|
-8.07%
|
-9.47%
|
-8.39%
|
-10.2%
|
-13.9%
|
-12.1%
|
Assets
1 |
527.4
|
589.4
|
843.4
|
787.2
|
665.4
|
671.1
|
Book Value Per Share
2 |
2.220
|
2.530
|
2.830
|
1.650
|
1.960
|
1.370
|
Cash Flow per Share
2 |
0.3300
|
0.4900
|
0.8500
|
0.4600
|
0.9300
|
0.2900
|
Capex
1 |
0.91
|
6.62
|
4.63
|
7.44
|
5.44
|
6.22
|
Capex / Sales
|
58.05%
|
74%
|
7.89%
|
6.95%
|
5.18%
|
5.26%
|
Announcement Date
|
3/28/19
|
3/27/20
|
3/26/21
|
3/25/22
|
3/23/23
|
3/27/24
|
|
1st Jan change
|
Capi.
|
---|
| +249.31% | 347M | | -1.17% | 104B | | +2.87% | 97.47B | | +4.40% | 22.25B | | -14.77% | 21.68B | | -8.70% | 18.2B | | -39.98% | 17.02B | | -13.21% | 16.36B | | +8.55% | 14.39B | | +35.75% | 12.37B |
Bio Therapeutic Drugs
|